2,3-di-O-benzyl-4,6-O-benzylidene-α-D-galactopyranosyl trichloroacetimidate | 150969-30-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡喃二恶英
• 英文名称: 2,3-di-O-benzyl-4,6-O-benzylidene-α-D-galactopyranosyl trichloroacetimidate
• 英文别名: [(4aR,6R,7R,8S,8aS)-2-phenyl-7,8-bis(phenylmethoxy)-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl] 2,2,2-trichloroethanimidate
• CAS: 150969-30-5
• 化学式: C₂₉H₂₈Cl₃NO₆
• 分子量: 592.903
• InChiKey: RUWQCKVLXFTLBX-NJTTWMPNSA-N

物化性质

• 沸点：
  627.0±65.0 °C(Predicted)
• 密度：
  1.39±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.9
• 重原子数：
  39
• 可旋转键数：
  9
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.34
• 拓扑面积：
  79.2
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  2,3-di-O-benzyl-4,6-O-benzylidene-α-D-galactopyranosyl trichloroacetimidate 在 palladium on activated charcoal chromium(VI) oxide 、 lithium hydroxide 、 高氯酸 、 三氟甲磺酸三甲基硅酯 、 4 A molecular sieve 、 硫酸 、 氢气 、 sodium methylate 作用下， 以 乙醚 、 乙醇 、 二氯甲烷 、 水 、 乙酸乙酯 、 丙酮 为溶剂， -70.0 ℃ 、98.06 kPa 条件下， 反应 52.0h， 生成 propyl 4-O-α-D-galactopyranosyl-β-D-glucopyranosiduronic acid
  参考文献：
  名称：

  Synthesis of structural elements of the capsular polysaccharide of streptococcus pneumoniae type 8

  摘要：

  The synthesis is reported of propyl 4-O-alpha-D-galactopyranosyl-beta-D-glucopyranosiduronic acid (25), 4-O-[4-O-(beta-D-glucopyranosyluronic acid)-beta-D-glucopyranosyl]-D-glucopyranose (34), and 4-O-(4-O-beta-D-glucopyranosyl-alpha-D-glucopyranosyl)-D-galactopyranose (38), each representing a structural element of the repeating unit of the capsular polysaccharide of Streptococcus pneumoniae type 8, [-->4)-beta-D-GlcpA-(1-->4)-beta-D-Glcp-(1-->4)-alpha-D-Glcp-(1-->4)-alpha-D-Galp-(1-->]n. 2,3-Di-O-benzyl-4,6-O-benzylidene-alpha-D-galactopyranosyl trichloroacetimidate (12) was coupled to allyl 2-0-acetyl-3-O-benzyl-6-0-trityl-beta-D-glucopyranoside (7) in dichloromethane-ether, using trimethylsilyl trifluoromethanesulfonate as a promoter, to give disaccharide derivative 20. Detritylation of 20, followed by oxidation and deprotection, afforded disaccharide propyl glycoside 25. Coupling of 2,3,4,6-tetra-0-acetyl-alpha-D-glucopyranosyl trichloroacetimidate (8) to allyl 2,3,6-tri-O-benzyl-4-O-(2,3,6-tri-O-benzyl-beta-D-glucopyranosyl)-beta-D-glucopyranoside (17) in dichloromethane, with trimethylsilyl trifluoromethanesulfonate as a promoter, resulted in trisaccharide derivative 26. Deacetylation of 26, followed by 6-O-tritylation, benzylation, detritylation, and oxidation gave a protected trisaccharide derivative (31), which, after deprotection, afforded 34. Coupling of allyl 2,3,6-tri-O-benzyl-beta-D-galactopyranoside (10) to 4-O-(2,3-di-O-benzyl-4,6-O-benzylidene-beta-D-glucopyranosyl)-2,3,6-tri-O-benzyl-D-glucopyranosyl trichloroacetimidate (19) in ether, with trimethylsilyl trifluoromethanesulfonate as a promoter, gave trisaccharide derivative 35. Deallylation of 35, followed by hydrogenolysis afforded 38.

  DOI：

  10.1016/s0040-4020(01)82378-4
• 作为产物：
  描述：

  allyl 2,3-di-O-benzyl-4,6-O-benzylidene-β-D-galactopyranoside 在 potassium tert-butylate 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 mercury dichloride 、 mercury(II) oxide 作用下， 以 二氯甲烷 为溶剂， 反应 6.0h， 生成 2,3-di-O-benzyl-4,6-O-benzylidene-α-D-galactopyranosyl trichloroacetimidate
  参考文献：
  名称：

  Synthesis of structural elements of the capsular polysaccharide of streptococcus pneumoniae type 8

  摘要：

  The synthesis is reported of propyl 4-O-alpha-D-galactopyranosyl-beta-D-glucopyranosiduronic acid (25), 4-O-[4-O-(beta-D-glucopyranosyluronic acid)-beta-D-glucopyranosyl]-D-glucopyranose (34), and 4-O-(4-O-beta-D-glucopyranosyl-alpha-D-glucopyranosyl)-D-galactopyranose (38), each representing a structural element of the repeating unit of the capsular polysaccharide of Streptococcus pneumoniae type 8, [-->4)-beta-D-GlcpA-(1-->4)-beta-D-Glcp-(1-->4)-alpha-D-Glcp-(1-->4)-alpha-D-Galp-(1-->]n. 2,3-Di-O-benzyl-4,6-O-benzylidene-alpha-D-galactopyranosyl trichloroacetimidate (12) was coupled to allyl 2-0-acetyl-3-O-benzyl-6-0-trityl-beta-D-glucopyranoside (7) in dichloromethane-ether, using trimethylsilyl trifluoromethanesulfonate as a promoter, to give disaccharide derivative 20. Detritylation of 20, followed by oxidation and deprotection, afforded disaccharide propyl glycoside 25. Coupling of 2,3,4,6-tetra-0-acetyl-alpha-D-glucopyranosyl trichloroacetimidate (8) to allyl 2,3,6-tri-O-benzyl-4-O-(2,3,6-tri-O-benzyl-beta-D-glucopyranosyl)-beta-D-glucopyranoside (17) in dichloromethane, with trimethylsilyl trifluoromethanesulfonate as a promoter, resulted in trisaccharide derivative 26. Deacetylation of 26, followed by 6-O-tritylation, benzylation, detritylation, and oxidation gave a protected trisaccharide derivative (31), which, after deprotection, afforded 34. Coupling of allyl 2,3,6-tri-O-benzyl-beta-D-galactopyranoside (10) to 4-O-(2,3-di-O-benzyl-4,6-O-benzylidene-beta-D-glucopyranosyl)-2,3,6-tri-O-benzyl-D-glucopyranosyl trichloroacetimidate (19) in ether, with trimethylsilyl trifluoromethanesulfonate as a promoter, gave trisaccharide derivative 35. Deallylation of 35, followed by hydrogenolysis afforded 38.

  DOI：

  10.1016/s0040-4020(01)82378-4

文献信息

• ESTERIFIED ALPHA-GALACTOSYLCERAMIDE
  申请人：Shiozaki Masao

  公开号：US20110224158A1

  公开（公告）日：2011-09-15

  The invention provides esterified α-galactosylceramides effective for cancer treatment and the like, and a medicament containing same. In particular, the invention relates to a compound represented by the formula (I): wherein R 1 is a hydrocarbon group having a carbon number of 1 to 30, R 2 is a hydrocarbon group having a carbon number of 1 to 20, R 3 is a hydrogen atom or hydrocarbon group having a carbon number of 1 to 5, R 4 and R 5 are the same or different and each is a hydrogen atom or a hydrocarbon group having a carbon number of 1 to 5, or R 4 and R 5 in combination form a divalent hydrocarbon group having a carbon number of 1 to 5, and optionally form a ring structure together with the adjacent ethylenedioxy, or a salt thereof.

  该发明提供了用于癌症治疗等的酯化α-半乳糖鞘氨醇，以及含有该酯化物的药物。具体来说，该发明涉及一种由以下式表示的化合物（I）： 其中R1是具有1至30个碳原子数的烃基，R2是具有1至20个碳原子数的烃基，R3是氢原子或具有1至5个碳原子数的烃基，R4和R5相同或不同，每个都是氢原子或具有1至5个碳原子数的烃基，或者R4和R5结合在一起形成具有1至5个碳原子数的二价烃基，且可选择地与邻近的乙二醚氧形成环结构，或其盐。
• Synthesis and Evaluation of Amino-Modified α-GalCer Analogues
  作者：Matthias Trappeniers、René Chofor、Sandrine Aspeslagh、Yali Li、Bruno Linclau、Dirk M. Zajonc、Dirk Elewaut、Serge Van Calenbergh

  DOI：10.1021/ol100934z

  日期：2010.7.2

  α-GalCer analogues featuring a phytoceramide 3- and 4-amino group have been synthesized. A Mitsunobu reaction involving phthalimide was employed for the introduction of the amino groups at the 3- and 4-positions of suitable phytosphingosine-derived precursors. The influence of these modifications on the interaction with the T-cell receptor of NKT cells was investigated, as well as the capacity of the

  已经合成了具有植物神经酰胺 3- 和 4- 氨基的 α-GalCer 类似物。使用涉及邻苯二甲酰亚胺的 Mitsunobu 反应在合适的植物鞘氨醇衍生前体的 3 位和 4 位引入氨基。研究了这些修饰对与 NKT 细胞的 T 细胞受体相互作用的影响，以及氨基修饰的类似物在体内给药后诱导细胞因子反应的能力。
• A divergent approach to the synthesis of iGb3 sugar and lipid analogues via a lactosyl 2-azido-sphingosine intermediate
  作者：Janice M. H. Cheng、Emma M. Dangerfield、Mattie S. M. Timmer、Bridget L. Stocker

  DOI：10.1039/c4ob00241e

  日期：——

  Isoglobotrihexosylceramide (iGb3, 1) is an immunomodulatory glycolipid that binds to CD1d and is presented to the T-cell receptor (TCR) of invariant natural killer T (iNKT) cells.

  异地三糖脂鞘氨醇（iGb3，1）是一种免疫调节糖脂，它结合到CD1d并呈现给不变天然杀伤T细胞受体（iNKT细胞）的T细胞受体（TCR）。
• Concise synthesis of clarhamnoside, a novel glycosphingolipid isolated from the marine sponge Agela clathrodes
  作者：Ning Ding、Chunxia Li、Yunpeng Liu、Zaihong Zhang、Yingxia Li

  DOI：10.1016/j.carres.2007.05.018

  日期：2007.10

  The first total synthesis of a novel alpha-galactoglycosphingolipid clarhamnoside has been achieved through a straightforward strategy. A thiogalactosyl donor with a benzylidene group at C-4 and C-6 and nonparticipating p-methoxybenzyl group at C-2 was successfully employed in the stereocontrolled syntheses of alpha-GalGSLs. The N-Phth-protected trifluoroacetimidate donor for terminal disaccharide

  通过简单的策略已经实现了新型α-半乳糖基鞘糖脂类香紫苏糖苷的第一个全合成。在C-4和C-6处具有亚苄基，在C-2处具有非参与性对甲氧基苄基的硫代半乳糖基供体已成功用于α-GalGSL的立体控制合成中。N-Phth保护的末端二糖的三氟乙酰亚氨酸供体已成功地用于构建[GalNAc beta-（1-> 6）-Gal]糖苷键。
• [EN] SPHINGAMIDE COMPOUNDS AND METHODS FOR BINDING INKT CELLS<br/>[FR] COMPOSÉS DE SPHINGAMIDE ET PROCÉDÉS DE LIAISON DE CELLULES INKT
  申请人：LA JOLLA INST ALLERGY & IMMUNOLOGY

  公开号：WO2017083830A1

  公开（公告）日：2017-05-18

  The compounds, compositions and methods provided herein antagonize, inhibit, decrease, reduce, suppress, or disrupt CD1d-mediated, iNKT cell-mediated, and/or iNKT cell TCR-mediated immune signaling. The sphingamide compounds were rationally designed based upon 3D structural considerations in relation to the structures of each of CD1d, the iNKT cell TCR, and the ternary complex CD1d-a-GalCer analog lipids-TCR. More specifically, the addition of an amide in the phytosphingosine tail of a derivative of ?-GalCer led to a non-conserved binding with CD1d, a conserved binding with the iNKT cell TCR, and an antagonist-like phenotype.

  这些化合物、组合物和方法在此处提供，对CD1d介导的、iNKT细胞介导的和/或iNKT细胞TCR介导的免疫信号进行拮抗、抑制、减少、降低、抑制或干扰。这些鞘胺化合物是根据与CD1d、iNKT细胞TCR以及三元复合物CD1d-a-GalCer类脂类-TCR的结构相关的三维结构考虑而合理设计的。更具体地说，将一种鞘磷酸鞘氨醇尾部的酰胺添加到?-GalCer衍生物中，导致与CD1d的非保守性结合、与iNKT细胞TCR的保守性结合以及拮抗剂样表型。